ENGOT-EN20/GOG-3083/XPORT-EC-042
Trial Description:
A Phase 3, Randomized, Placebo-Controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma
Lead Cooperative Group:
Trial Number:
EudraCT: 2022-02540-42
Disease Site:
Endometrial
Trial Status:
Pending